logo
  

Novartis Invests $250 Mln To Advance R&D Of Treatments Against Neglected Tropical Diseases & Malaria

Novartis (NVS) said it will invest $250 million to advance research and development of new treatments to combat neglected tropical diseases and malaria, as part of its commitment over five years (2021-2025).

The commitment includes $100 million to advance R&D for Chagas disease, leishmaniasis, dengue and cryptosporidiosis, and $150 million for next-generation antimalarials and a new formulation for babies under 5kg with malaria.

"Today, by endorsing the Kigali Declaration and pledging to invest USD 250 million, we aim to accelerate progress toward elimination of these diseases, which continue to cause suffering and stigma for millions of people around the globe," said Vas Narasimhan, CEO of Novartis.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT